

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

FLEMINGTON PHARMACEUTICAL CORP
Form 10QSB
March 18, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the six month period ended January 31, 2002

TRANSITION REPORT UNDER SECTION 13 or 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the transition period from _____ to _____

Commission file number 000-23399

FLEMINGTON PHARMACEUTICAL CORPORATION
(Exact name of small business issuer as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

22-2407152
(I.R.S. Employer
Identification No.)

31 State Highway 12
Flemington, New Jersey
(Address of Principal Executive Offices)

08822
(Zip Code)

(908)782-3431
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PRECEDING FIVE YEARS:

Check whether the registrant filed all documents and reports required to
be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution
of securities under a plan confirmed by a court. Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date. 14,391,567 shares of common
stock outstanding as of March 14, 2002.

TRANSITIONAL SMALL BUSINESS DISCLOSURE FORMAT (check one): Yes No

FLEMINGTON PHARMACEUTICAL CORPORATION

BALANCE SHEETS

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

	January 31, 2002 ----- (Unaudited)	July 31, 2001 -----
ASSETS		
CURRENT ASSETS:		
Cash	\$ 3,246,000	\$ 585,000
Accounts receivable - trade, less allowance for doubtful accounts of \$15,000 at January 31, 2002 and \$9,000 at July 31, 2001	138,000	92,000
Prepaid expenses and other current assets	92,000	57,000
	-----	-----
Total Current Assets	3,476,000	734,000
	-----	-----
FURNITURE, FIXTURES, AND EQUIPMENT, LESS ACCUMULATED DEPRECIATION	220,000	167,000
DEMAND NOTE RECEIVABLE, OFFICER	-	60,000
DUE FROM JOINT VENTURE PARTNER FOR REIMBURSABLE EXPENSES	10,000	6,000
OTHER ASSETS	18,000	17,000
	-----	-----
	\$ 3,724,000	\$ 984,000
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)		
CURRENT LIABILITIES:		
Accounts payable trade	\$ 125,000	\$ 11,000
Accrued expenses	226,000	77,000
	-----	-----
Total Current Liabilities	351,000	88,000
	-----	-----
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY (DEFICIENCY):		
Preferred stock, \$.01 par value:		
Authorized 1,000,000 shares, none issued		
Common stock, \$.001 par value:		
Authorized 50,000,000 shares		
Issued and outstanding - 11,724,900 shares in 2002 and 7,724,900 shares in 2001		
	12,000	8,000
Additional paid-in capital	9,431,000	6,411,000
Accumulated Deficit	(6,070,000)	(5,523,000)
	-----	-----
Total Stockholders' Equity (Deficiency)	3,373,000	896,000
	-----	-----
	\$3,724,000	\$ 984,000
	=====	=====

See accompanying notes to financial statements.

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

FLEMINGTON PHARMACEUTICAL CORPORATION

STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended January 31,		Six Months Ended January 31,	
	2002	2001	2002	2001
CONSULTING REVENUES	\$ 183,000	\$ 76,000	\$ 255,000	\$ 141,000
CONSULTING, SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	548,000	467,000	872,000	894,000
LOSS FROM OPERATIONS	(365,000)	(391,000)	(617,000)	(753,000)
BUYOUT OF CONSULTANT'S CONTRACT	(33,000)	-	(33,000)	-
INTEREST INCOME	10,000	3,000	15,000	13,000
NET LOSS BEFORE TAXES	(388,000)	(388,000)	(635,000)	(740,000)
DEFERRED INCOME TAX BENEFIT	88,000	47,000	88,000	47,000
NET LOSS	\$ (300,000)	\$ (341,000)	\$ (547,000)	\$ (693,000)
BASIC AND DILUTED LOSS PER SHARE	\$ (.03)	\$ (.06)	\$ (.06)	\$ (.12)
SHARES USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE	9,942,291	5,881,237	8,833,596	5,879,889

See accompanying notes to financial statements.

-3-

FLEMINGTON PHARMACEUTICAL CORPORATION

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Unaudited)

	Common Stock				Stockholders' Equity (Deficiency)
	Shares	Par Value	Paid-in Capital	Accumulated Deficit	
BALANCE, JULY 31, 2001	7,724,900	\$ 8,000	\$6,411,000	\$ (5,523,000)	\$ 896,000

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

SIX MONTHS ENDED JANUARY 31, 2002 In Connection with private placement, net of costs	4,000,000	4,000	2,980,000	-	2,984,000
Warrants issued for services	-	-	40,000	-	40,000
Net Loss	-	-	-	(547,000)	(547,000)

BALANCE, JANUARY 31, 2002	11,724,900	\$12,000	\$9,431,000	\$(6,070,000)	\$ 3,373,000
=====					

See accompanying notes to financial statements.

-4-

FLEMINGTON PHARMACEUTICAL CORPORATION

STATEMENT OF CASH FLOWS
(Unaudited)

	Six Months Ended January 31,	
	2002	2001

CASH FLOW FROM OPERATING ACTIVITIES:		
Net (loss)	\$ (547,000)	\$ (693,000)
Adjustments to reconcile net income (loss) to net cash flows from operating activities:		
Warrants issued for Services	40,000	-
Shares Issued for Services	-	6,000
Depreciation & Amortization	28,000	8,000
Allowance for Doubtful Accounts	6,000	-
Changes in operating assets and liabilities:		
Accounts receivable	(52,000)	(3,000)
Due from D&O Insurance Carrier	-	64,000
Prepaid expenses and other current assets	(35,000)	15,000
Demand note receivable, officer	60,000	-
Due from joint venture partner for reimbursable expenses	(4,000)	63,000
Other Assets	(1,000)	(11,000)
Costs and estimated earnings in excess of billings on uncompleted contracts	-	(10,000)
Accounts payable - trade	114,000	110,000
Billings in excess of costs and estimated earnings on uncompleted contracts	-	(29,000)
Accrued expenses and other current liabilities	149,000	(12,000)
	-----	-----
Net cash flows from operating activities	(242,000)	(492,000)
	-----	-----
CASH FLOWS FROM INVESTING ACTIVITIES -		

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

Purchase of property and equipment	(81,000)	(56,000)
	-----	-----
CASH FLOWS FROM FINANCING ACTIVITIES -		
Proceeds received from issuance of common stock through a private placement offering	2,984,000	-
	-----	-----
NET CHANGE IN CASH	2,661,000	(548,000)
CASH, BEGINNING OF PERIOD	585,000	700,000
	-----	-----
CASH, END OF PERIOD	3,246,000	152,000
	=====	=====
SUPPLEMENTAL CASH FLOW INFORMATION:		
Interest paid	\$ -	\$ -
	=====	=====
Income taxes paid	\$ -	\$ -
	=====	=====

See accompanying notes to financial statements.

-5-

FLEMINGTON PHARMACEUTICAL CORPORATION

NOTES TO FINANCIAL STATEMENTS

Note 1 - Basis of Presentation:

The balance sheet at the end of the preceding fiscal year has been derived from the audited balance sheet contained in the Company's Form 10-KSB and is presented for comparative purposes. All other financial statements are unaudited. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the financial position, results of operations and cash flows for all periods presented, have been made in the interim statements. Results of operations for interim periods are not necessarily indicative of the operating results for a full year.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has had a history of recurring losses from operations, giving rise to an accumulated deficit through January 31, 2002. Resulting operating losses and negative cash flows from operations are likely to occur until, if ever, profitability can be achieved through successful marketing of the Company's developed products.

Footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted in accordance with the published rules and regulations of the Securities and Exchange Commission. The financial statements in this report should be read in conjunction with the financial statements and notes thereto included in the Form 10-KSB of Flemington Pharmaceutical Corporation (the "Company"), for the year ended July 31, 2001.

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

Note 2 - Stockholder's Note Receivable:

During January 2002, the Company's President repaid a \$60,000; 7% demand loan and approximately \$5,000 accrued interest to the Company. The Company granted this loan during April 1998.

Accrued expenses:

Approximately \$100,000 of accrued clinical study costs for clients, approximately \$70,000 of accrued employee vacation and approximately \$26,000 of accrued salary and related payroll taxes due to three (3) of the company's officers are included in the \$226,000 total. The remainder is other current liabilities.

Note 3 - Private Placement:

During December 2001, the Company received net proceeds of approximately \$2,984,000 from a private placement of 4,000,000 Units of the Company's securities. Each Unit consisted of a common share, par value \$.001, and a warrant to purchase an additional share of the company's common stock at an exercise price of \$0.75 within seven (7) years. The sale price of each Unit was \$0.75. The Private Placement agreement also provided for an additional placement of 2,666,667 units on or before June 12, 2002. See also Subsequent Events (Note 7).

-6-

Note 4 - Stock Options and Warrants

Pursuant to an employment agreement dated September 4, 2001, and an amendment in December 2001, the Company granted 1,050,000 non-plan options to Robert C. Galler, a director and officer of the Company. The term of the options is ten years and the exercise price is \$.75 per share. 700,000 of these options vested in December 2001. An additional 350,000 options will be issued to Mr. Galler if certain conditions in his employment agreement are achieved. The Company applies Accounting Principle Board Opinion No. 25, "Accounting for Stock Issued to Employees" and the related interpretations in accounting for its stock options to employees. See also Note 6.

During December 2001, the Company granted an aggregate of 100,000 stock options under the Company's 1998 option plan, exercisable at \$0.80 per share for a term of ten (10) years, to four (4) non-managerial employees. The Company applies Accounting Principle Board Opinion No. 25, "Accounting for Stock Issued to Employees" and the related interpretations in accounting for its stock options to employees.

During December 2001, the Company extended the term of 50,000 options previously granted to each of the Company's CEO and Chairman, respectively. These options, previously set to expire on March 25, 2003, now expire on December 10, 2006. All other terms of the options remain unchanged. In accordance with Financial Interpretation No. 44, "Accounting for certain transactions involving Stock Compensation (Interpretation of APB opinion No. 25), no expense was recorded because the exercise price of the option was higher than the price of the common stock on the date that the life of the options was extended.

During December 2001, the Company's Board of Directors acted to increase

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

the number of options provided by the Company's 1998 option plan from 500,000 to 1,075,000. The Board's action in this respect was submitted for ratification by the shareholders at the Company's 2001 Annual Meeting, held February 15, 2002, at which it was approved.

During December 2001, to buy-out a contract with a consultant, the Company agreed to issue 50,000 warrants, having a term of seven (7) years, to purchase the Company's common stock at \$0.75 per share, in exchange for which all relationships between the Company and the consultant were terminated. An expense of \$33,000 was recorded to recognize the settlement.

In January 2002, pursuant to an agreement with The Trout Group, LLC (see Note 6, below), the Company issued warrants to purchase 60,000 shares of common stock at an exercise price of \$2.00 per share. The warrants have a 5-year life and vest quarterly through October 1, 2002.

Note 5 - Deferred income tax benefit:

On December 19, 2001, the Company received approximately \$88,000 as consideration for transferring approximately \$1,159,000 of New Jersey net operating loss tax benefit to a third party corporation buyer. The Technology Tax Certificate Transfer Program for transferring net operating loss and R & D tax benefits is the responsibility of New Jersey Economic Development Authority.

Note 6 - Contracts:

In September, 2001 the Company entered into an employment agreement with Robert Galler, who became Vice President - Corporate Development and a Director of the Company. The Agreement was amended in December, 2001. Under the Agreement as amended, Mr. Galler was hired for a period of three years, at a base salary of \$180,000 per year. See also Note 4.

-7-

During January 2002, the Company entered into a consulting agreement, and will pay \$25,000 per quarter through December 31, 2002 for investor relations with The Trout Group, LLC. See also Note 4.

Note 7 - Subsequent Events:

In February 2002 the Company entered into an employment agreement, effective January 1, 2002, with its President, Harry A. Dugger III. The Agreement has a term of three years and provides for a base salary of \$248,000 per year.

In February, 2002 the Company entered into an employment agreement, effective January 1, 2002, with its Chief Financial Officer, Donald Deitman. The Agreement has a term of three years and provides for a base salary of \$125,000 per year.

In February 2002 the Company entered into a consulting agreement for the rendition of advice regarding strategic transactions. The Agreement has a term of one year, and is renewable annually thereafter. The Agreement provides for base fees of \$300,000 per year, with additional compensation payable for the achievement of certain goals set forth in the Agreement. Upon execution of this agreement, 1,000,000 options were issued with a 10

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

year life at an exercise price of \$2.40 per common share. The options vest and become exercisable in three equal annual installments commencing February 1, 2003. In addition, in February 2002, this consultant was elected as a member and Chairman of the Company's Board of Directors.

In February 2002, the board issued non-plan options to outside directors. 75,000 options were issued to each of two directors and 37,500 options to one director. These options have an exercise price of \$2.69 and a term of 10 years.

During March 2002, the Company amended the private placement agreement referred to in Note 3, above to accelerate the placement of the additional 2,666,667 units of the Company's securities, which such placement closed simultaneously with the signing of the amendment. Net proceeds from this portion of the placement was approximately \$1,990,000. Each unit consisted of a common share, par value \$.001, and a warrant to purchase an additional share of the Company's common stock.

-8-

FLEMINGTON PHARMACEUTICAL CORPORATION

Part I, Item 2. Management's Discussion and Analysis

Flemington Pharmaceutical Corporation, a New Jersey corporation (the "Company"), is engaged in the development of novel application drug delivery systems for presently marketed prescription and over-the-counter ("OTC") drugs and been a consultant to the pharmaceutical industry. Since 1992, the Company has used its consulting revenues to fund its own product development activities.

Since its inception, substantially all of the Company's revenues have been derived from its consulting activities. The Company has had a history of recurring losses from operation, giving rise to an accumulated deficit at January 31, 2002 of approximately \$6,070,000. Revenues from consulting may be expected to decline in the future as the Company shifts its emphasis away from product development consulting for its clients and towards development of its own products.

For the reasons stated above, the Company anticipates that it will incur substantial operating expenses in connection with the testing and approval of its proposed delivery systems, and expects these expenses will result in continuing and significant operating losses until such time, if ever, that the Company is able to achieve adequate sales levels.

Results of Operations

The six months ended January 2002 [the "2002 Period"] and January 2001 [the "2001 Period"]

Operating revenues for the 2002 Period increased approximately \$114,000 or 81% to \$255,000 from \$141,000 for the 2001 Period. This revenue increase for

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

the 2002 period was primarily attributable to an increase in clinical studies for clients.

Total costs and expenses for the 2002 Period increased approximately \$11,000 or 1% to \$905,000 from \$894,000 for the 2001 Period. This increase includes an approximate \$48,000 in legal & professional fees, an approximate \$33,000 in buy-out of contract with a consultant (see note 4), an approximate \$20,000 in payroll expense primarily due to the establishment of a vacation pay accrual, an approximate \$20,000 in depreciation and amortization expense due to the earlier purchase of internal laboratory equipment, an approximate \$13,000 in rent expenses due to increased rents for the Company's facilities, occupied in October 2000, and the establishment of the Company's Florida office during October 2001, an approximate \$11,000 in public company expenses due primarily to an increase in the number of outside directors and the increased number of board meetings held during the 2002 period, an approximate \$8,000 in trade show and conference expenses and an approximate \$6,000 in bad debt expense.

Costs and expenses decreases for the 2002 period, as compared to the 2001 period, includes an approximate \$100,000 in laboratory testing and clinical studies costs due primarily to the Company's earlier decision to establish an internal laboratory and an approximate \$51,000 in outside consulting fees due to the internalization of some consulting functions.

Interest income increased approximately \$2,000 or 15% to \$15,000 for the 2002 Period from \$13,000 for the 2001 Period due to an increased average cash balance in conjunction with reduced interest rates for the 2002 period.

Deferred income tax benefit for the 2002 period was approximately \$88,000 compared to approximately \$47,000 for the 2001 period. These benefits resulted from the sale of the Company's New Jersey net operating losses.

The resulting net loss for the 2002 Period was \$547,000 compared to a net loss of \$693,000 for the 2001 Period.

The three months ended January 2002 [the "2002 Period"] and January 2001 [the "2001 Period"]

Operating revenues for the 2002 Period increased approximately \$107,000 or 141% to \$183,000 from \$76,000 for the 2001 Period.

Total costs and expenses for the 2002 Period increased approximately \$114,000 or 24% to \$581,000 from \$467,000 for the 2001 Period. This increase includes an approximate \$92,000 in payroll expense primarily due to the establishment of a vacation pay accrual, an approximate \$33,000 in buy-out of consultant's contract (see note 4), an approximate \$12,000 in public company expenses due primarily to an increase in the number of outside directors and the increased number of board meetings held during the 2002 period, an approximate \$11,000 in depreciation and amortization expense due to the earlier purchase of internal laboratory equipment, an approximate \$8,000 in trade show and conference expenses, an approximate \$6,000 in bad debt expense, an approximate \$5,000 in inside laboratory supplies expenses and an approximate \$5,000 in rent expenses.

Costs and expenses decreases for the 2002 period, as compared to the 2001 period, includes an approximate \$54,000 in laboratory testing and clinical studies costs due primarily to the Company's earlier decision to establish an internal laboratory, an approximate \$9,000 in outside consulting fees due to the internalization of some consulting functions and an approximate \$9,000 in insurance expenses due primarily to fewer employees requiring medical insurance coverage.

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

Interest income increased approximately \$7,000 or 233% to \$10,000 for the 2002 Period from \$3,000 for the 2001 Period due to an increased average cash balance.

Deferred income tax benefit for the 2002 period was approximately \$88,000 compared to approximately \$47,000 for the 2001 period. These benefits resulted from the sale of the Company's New Jersey net operating losses.

The resulting net loss for the 2002 Period was \$300,000 compared to a net loss of \$341,000 for the 2001 Period.

-9-

Liquidity and Capital Resources

Net cash used in operating activities approximated \$242,000 for the 2002 Period compared to net cash used in operating activities of approximately \$492,000 for the 2001 Period. Net cash used in operating activities for both the 2002 and 2001 periods was primarily attributable to the net loss of \$547,000 and \$693,000, respectively. For the 2002 Period, \$81,000 was used for investing activities compared to \$56,000 for the 2001 Period. Total cash flow for the 2002 period increased approximately \$2,661,000 as compared to a \$548,000 decrease for the 2001 period.

During March 2002, the Company received net proceeds of approximately \$1,990,000 from a private placement of the Company's common stock (see Note 3). The Company believes that it currently has sufficient cash to satisfy its cash requirements for at least the next twenty four (24) months.

Inflation

The Company does not believe that inflation has had a material effect on its results of operations during the past three fiscal years. There can be no assurance that the Company's business will not be affected by inflation in the future.

-10-

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

N/A

Item 2. Changes in Securities

On December 12, 2001, the Company issued 4,000,000 shares of its common stock to an accredited investor pursuant to Rule 506 of Regulation D of the Securities Act of 1933, as amended. The company sold such shares at \$.75 per share resulting in net proceeds of approximately \$2,984,000.

Edgar Filing: FLEMINGTON PHARMACEUTICAL CORP - Form 10QSB

Item 3. Defaults Upon Senior Securities

N/A

Item 4. Submissions of Matters to a Vote of Security Holders

N/A

Item 5. Other Information

N/A

Item 6. Exhibits and Reports on Form 8-K

a) Exhibits

Exhibit 11. Statement re: computation of earnings per share for the six months ended January 31, 2002

b) Reports on Form 8-K

-11-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

FLEMINGTON PHARMACEUTICAL CORPORATION

By: /s/ Harry A. Dugger, III

Harry A. Dugger, III, President
(Principal Executive Officer)

By: /s/ Donald J. Deitman

Donald J. Deitman, Chief Financial Officer

-12-

EXHIBIT 11

FLEMINGTON PHARMACEUTICAL CORPORATION

EARNINGS PER SHARE COMPUTATION

(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(UNAUDITED)

	SIX MONTHS ENDED JANUARY 31, 2002
	----- BASIC -----
Weighted average shares outstanding	8,833,596
Dilutive effect of stock performance plans (1)	-
Total	8,833,596
Net Income (loss)	(547)
Earnings per share	(.06)

	SIX MONTHS ENDED JANUARY 31, 2001
	----- BASIC -----
Weighted average shares outstanding	5,879,889
Dilutive effect of stock performance plans (1)	-
Total	5,879,889
Net Income (loss)	(693)
Earnings per share	(.12)

(1) No potential shares from stock performance plans have been presented, as their effect would be anti-dilutive

